NEWAMSTERDAM PHARMA CO NV (NAMS)
NL00150012L7 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 97.5M | 13.254M -86.41% | 32.335M 143.96% | 10.442M -67.71% | 20.308M 94.48% | 125.02M 515.62% | 319.45M 155.52% | 593.18M 85.69% | 944.39M 59.21% | 1.205B 27.60% | |||
| EBITDA YoY % growth | -126.66K | -1.352M -967.65% | -3.867M -185.96% | -238.852M -6,076.67% | -192.78M 19.29% | -146.88M 23.81% | -95.88M 34.72% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -127.66K | -1.366M -970.25% | -3.939M -188.30% | -195.241M -4,856.62% | -189.846M 2.76% | -200.597M -5.66% | -200.229M 0.18% | -144.506M 27.83% | -3.004M 97.92% | 189.18M 6,397.35% | 481.25M 154.39% | 762.17M 58.37% | |
| Operating Margin | N/A | N/A | -4.04% | -1,473.07% | -587.12% | -1,921.06% | -985.96% | -115.59% | -0.94% | 31.89% | 50.96% | 63.25% | |
| EPS YoY % growth | N/A | N/A | N/A | -2.21 -1,306.89% | -2.15 2.68% | -1.91 10.87% | -1.79 6.34% | -1.28 28.69% | 0.21 116.06% | 1.94 847.04% | 4.25 118.69% | 5.39 26.80% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.53 9.10% | -0.50 53.09% | -0.49 -20.66% | -0.48 -164.92% | -0.47 11.16% | -0.43 13.85% | -0.44 11.34% | -0.46 3.03% | -0.49 -3.62% |
| Revenue Q2Q % growth | 1.762M 123.72% | -100.00% | -100.00% | -100.00% | -100.00% | 183.6K | 367.2K | 612K | 856.8K |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -54.099M -3.10% | -52.084M -2.63% | -51.769M 9.25% | -49.033M 6.60% | -47.529M 12.15% | -41.49M 20.34% | -43.295M 16.37% | -46.703M 4.75% | -51.513M -8.38% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.18 67.54% | -0.51 | 0.33 | 64.67% |
| Q2 2024 Q2Q % growth | -0.41 11.09% | -0.59 | 0.18 | 30.32% |
| Q1 2024 Q2Q % growth | -1.06 -163.31% | -0.54 | -0.52 | -97.14% |
| Q4 2023 Q2Q % growth | -0.58 -26.72% | -0.61 | 0.03 | 4.67% |
| Q3 2023 Q2Q % growth | -0.55 4.59% | -0.50 | -0.06 | -11.52% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 29.111M 877.73% | 1.91M | 27.201M | 1,424.14% |
| Q2 2024 Q2Q % growth | 2.279M -76.17% | 1.406M | 873K | 62.09% |
| Q1 2024 Q2Q % growth | 1.401M -45.10% | 1.778M | -377K | -21.20% |
| Q4 2023 Q2Q % growth | 787.59K -99.19% | 1.998M | -1.21M | -60.58% |
| Q3 2023 Q2Q % growth | 2.977M | 2.291M | 686.42K | 29.96% |
| Q2 2023 Q2Q % growth | 9.562M | 2.794M | 6.768M | 242.23% |
| Q4 2022 Q2Q % growth | 97.5M | 3.561M | 93.939M | 2,637.99% |
| Q3 2022 Q2Q % growth | 1.687M | -1.687M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 0% | -16.39% |
| Revenue | 0% | 0% | 0% | 86.41% |